Hemispherx Biopharma Receives New Patent for Intranasal Ampligen
Hemispherx Biopharma, Inc. recently announced the granting of a new United States Patent for the use of Ampligen as a vaccine adjuvant for use with seasonal influenza vaccine to induce an enhanced immune response against H5N1 avian influenza. The patent describes a method using intranasal administration of Ampligen, a toll-like receptor 3 (TLR3) agonist, along with a seasonal influenza vaccine to enhance an immune response against a H5N1 avian influenza infection compared to the administration of seasonal influenza vaccine alone. Intranasal vaccination stimulates mucosal immunity, which is characterized by a broader, and potentially more effective, immune response.
Influenza epidemics continue to represent a significant medical challenge. Even with existing vaccines, annual influenza epidemics typically result in 20 to 50 million cases, resulting in 30,000 to 40,000 deaths in the
FDA authorization of a clinical trial to evaluate the breadth of immunological protection in healthy volunteers, potentially conveyed by Ampligen, an experimental therapeutic, against influenza viruses has been recently announced.
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen and Alferon LDO. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. The company’s platform technology includes components for potential treatment of various severely debilitating and life-threatening diseases.
Total Page Views: 1546
